PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1570867
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1570867
Dupuytrens Disease Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Dupuytren's Disease Therapeutics Market was valued at approximately USD 889.4 million in 2023 and projections indicate a growth rate of 12.2% CAGR from 2024 to 2032. Dupuytren's disease, also known as Dupuytren's contracture, is a progressive hand deformity affecting a tissue layer beneath the palm's skin. Over time, tissue knots form, leading to a thick cord that can bend one or more fingers. The increasing prevalence of Dupuytren's disease significantly drives the market. Advancements in drug delivery technologies and a growing geriatric population further bolster market growth. Recent years have seen significant strides in Dupuytren's disease therapeutics, with a clear shift towards treatments that are both more effective and less invasive, supporting their popularity and market growth.
The overall dupuytrens disease therapeutics industry is classified based on the type, therapeutics, distribution channel and region.
Segmented by type, the Dupuytren's disease therapeutics market includes type I, type II, and type III. Projections indicate the type II segment will reach USD 1.3 billion by 2032. Type II leads the market as the most common form of the disease, acting as an intermediary between the milder type I and the more severe type III. As finger contracture becomes more evident in type II, patients are more likely to seek medical intervention, driving treatment demand. Treatments like collagenase injections or surgery are most effective during the type II stage, enhancing revenue growth.
Segmented by therapeutics, the Dupuytren's disease therapeutics market includes collagenase injections, steroids, immune-modulators, and other treatments. In 2023, collagenase injections made up USD 489.2 million of the market. Collagenase injections offer a minimally invasive solution, injecting the enzyme into the affected collagen cords and eliminating the need for surgical cuts. This enzyme breaks down the collagen cords causing contractures, improving finger extension and hand function. Collagenase injections can address multiple fingers or joints at once, making it a flexible choice for patients with widespread contractures, thus propelling market growth.
Germany's Dupuytren's disease therapeutics market is set to reach USD 234.4 million by 2032, driven by a strong focus on research and development (R&D) and innovations in medical treatments. Germany emphasizes R&D, hosting top-tier pharmaceutical firms and renowned research institutions that collaborate closely to drive breakthroughs in both drug development and surgical techniques for treating Dupuytren's disease. These institutions benefit from well-established healthcare infrastructure and access to cutting-edge technology, enabling the continuous exploration of new treatment methods, such as minimally invasive procedures and biologic therapies.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence for dupuytren's disease
- 3.2.1.2 Advancements in drug delivery technologies
- 3.2.1.3 Rising geriatric population
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High research and development cost
- 3.2.2.2 Potential side effects and complications
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
- 3.7 Future market trends
- 3.8 Pipeline analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Type I
- 5.3 Type II
- 5.4 Type III
Chapter 6 Market Estimates and Forecast, By Therapeutics, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Collagenase injection
- 6.3 Steroids
- 6.4 Immune-modulators
- 6.5 Other therapeutics
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Retail pharmacy
- 7.3 Hospital pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Europe
- 8.2.1 Germany
- 8.2.2 UK
- 8.2.3 France
- 8.2.4 Spain
- 8.2.5 Italy
- 8.2.6 Netherlands
- 8.2.7 Rest of Europe
- 8.3 North America
- 8.3.1 U.S.
- 8.3.2 Canada
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AstraZeneca PLC
- 9.2 Actiza Pharmaceutical Private Limited
- 9.3 Bayer AG.
- 9.4 Bristol-Meyers Squibb Company
- 9.5 Endo International plc
- 9.6 Fresenius SE and Co. KGaA
- 9.7 Fortress Biotech, Inc.
- 9.8 GSK plc
- 9.9 Hikma Pharmaceuticals PLC
- 9.10 Johnson and Johnson
- 9.11 Merck and Co., Inc.
- 9.12 Nantong Jinghua Pharmaceutical Co., Ltd
- 9.13 Novartis AG
- 9.14 LEO Pharma A/S
- 9.15 Pfizer Inc.
